Hemoglobinopathies Market Size & Forecast Report, 2012 - 2022

The global Hemoglobinopathies Market size is expected to value at USD 8.82 billion by 2022. The hemoglobinopathies industry is subject to witness a substantial growth due to the growing prevalence of hemoglobinopathies, particularly in underdeveloped economies such as South East Asia, Middle East region, and Africa. In addition, increasing number of high unmet needs for diagnosis and treatment of these disorders is expected to fuel the growth of hemoglobinopathies market over the next seven years. Globally, the hemoglobinopathies industry is predicted to grow at higher CAGR in the forecast period, providing numerous opportunities for market players to invest for research and development in the market.

Hemoglobinopathy is commonly known as a genetic defect, which results in abnormal structure of single globin chains of the hemoglobin molecule. Hemoglobinopathies are hereditary or inherited single gene disorders. The hemoglobinopathies are also referred as autosomal co-dominant traits disorders. However, lack of awareness among general population and lack availability of healthcare facilities in rural areas in developing economies are considered as major challenges for sustained market growth. Yet, rise in number of research & development activities in European region and favorable laws & regulation by local governments are expected to offer lucrative growth opportunities for industry players over the forecast period.

Rising mortality rate, particularly diseases such as sickle cell disease (SCD) and thalassemia are expected to generate demand for hemoglobinopathies. Additionally, favorable government laws & regulations coupled with growing investment by local governments are estimated to stimulate the growth of hemoglobinopathies market in the near future. Substantial focus has been given towards spreading awareness about diseases such as sickle cell disease (SCD) and thalassemia, and development of Hemoglobinopathies (RuSH) are predicted to boost market growth over the forecast period.

The hemoglobinopathies industry is divided into thalassemia (alpha and beta), sickle cell diseases, and other hemoglobinopathies such as hereditary elliptocytosis based type of therapy. Gene mutations is primary cause of different of hereditary conditions producing blood disorders such as thalassemia and Sickle Cell Disease (SCD); they occur due to encoding of the globins.

The hemoglobinopathies market is divided by region as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rise in the implementation of latest technologies in medicine & pharmaceutical sector, increase in the number of research & development activities in the region, and existence of well-established healthcare infrastructure.

Asia-Pacific region is predicted to hold major market share in the hemoglobinopathies with massive growth in forecast period. Countries such as India, China, South Korea and Singapore are leading the Asia-Pacific market with rising healthcare expenditure in the region, growing awareness among general population, increasing disposable income, and significant investment by leading industry players considering potential growth opportunities in the region.

The key players in the hemoglobinopathies industry are Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences, Genetix Pharmaceuticals Inc., Global Blood Therapeutics, Mast Therapeutics, Emmaus Medical, Inc., Prolong Pharmaceuticals, Calgene Corporation, Invenux LLC, Optinova Ab, Anthera Pharmaceuticals, HemaQuest Pharmaceuticals, and Acceleron Pharma.

Market Segment:

Global Hemoglobinopathies Therapy Outlook (Revenue, USD Million), 2012 - 2022
    • Thalassemia
        • Alpha thalassemia
        • Beta thalassemia
    • Sickle cell disease
    • Hemoglobin variants diseases

Global Hemoglobinopathies Diagnosis Outlook (Revenue, USD Million), 2012 - 2022
    • Thalassemia
        • Alpha thalassemia
        • Beta thalassemia
    • Sickle cell disease
    • Hemoglobin variants diseases

Hemoglobinopathies Regional Outlook (Revenue, USD Million), 2012 - 2022
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • UK
    • Asia Pacific
        • Japan
        • China
    • Latin America
        • Brazil
        • Mexico
    • MEA
        • South Africa